Abstract 19672: Comparison of Major-bleeding Risk and Health Care Costs Among Treatment-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or WarfarinAlpesh Amin, Jeffrey Trocio, Jack Mardekian et al.|Circulation|2015Cited by 4
Comparison of Short-Term Bleeding-Related Health Care Utilization and Costs Among Treatment-Naïve Nonvalvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or WarfarinAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|CHEST Journal|2015Cited by 3
Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarinAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|MEF University Institutional Repository (MEF University)|2015Cited by 2
Real-world comparison of major bleeding and associated costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban or warfarinAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|MEF University Institutional Repository (MEF University)|2016Cited by 0